Sina Habibi, CEO of Cognetivity Neurosciences, spoke with INN about the company’s partnership with DPUK and additional plans for 2019.
At the recent Cantech Investment Conference, Sina Habibi, CEO of Cognetivity Neurosciences (CSE:CGN,OTCQB:CGNSF) spoke with the Investing News Network (INN) about the company’s partnership with the Dementia Platform UK (DPUK) and additional plans for 2019.
Habibi said the company will be putting more efforts into its artificial intelligence (AI) platform and collecting more data as it seeks to train its solutions to detect mental health disorders, like attention deficit hyperactivity disorder (ADHD). As it currently stands, Cognetivity is using AI and machine learning to aid in the early detection of dementia and Alzheimer’s disease.
On that note, in addition to the DPUK partnership, Habibi spoke to INN about a health application the company has that could be launched by the end of 2019.
Below is a transcript of our interview with Habibi. The transcript has been edited for clarity and brevity. Read on for more of what Habibi had to say.
INN: For investors who aren’t familiar with Cognetivity Neurosciences, could you explain a little bit about your company for us?
SH: We are a spinoff from Cambridge University in the United Kingdom and we went public in Canada last March. The company has an artificial intelligence solution for early detection of mental health disorders, in particular dementia and Alzheimer’s.
INN: You recently announced that your company had teams with the Dementia Platform in the UK. Can you explain a little about that to us?
SH: We all know that we have a problem, a huge problem, with dementia. In fact, it’s the biggest health care challenge of the 21st century. Dementia Platform UK is an initiative which was brought in by Oxford University and the idea is to bring in academic research centers, companies, pharma companies, and industrial partners in order to work together in order to come up with treatments and solutions for detection of dementia. We are proud to be the ninth partner of this consortium, which has up to two million cohort occupations that are a part of this program. The other partners include Cambridge University, Oxford University, GSK (LSE:GK), and AstraZeneca (LSE:AZN). So you could see the league of partners is quite high profile and the target is quite important.
INN: You had mentioned dementia and mental health issues, but your technology can also be used for other illnesses as well.
SH: Absolutely. We have done most of our clinical work on Alzheimer’s but we’re not limited to that. Because of some really interesting data on multiple sclerosis, we believe it can use the platform technology in order to detect other mental health disorders, such as ADHD. We all need to look into it in-depth, collect some data and train our AI to see a very confined trends, but we believe we can do that.
INN: What other technologies are you looking to include into the Cognetivity Neurosciences brand?
SH: At the moment we’re focused on building this AI engine further and further … to collect more data. But we can use these as an adjunct to beat all other technologies such as virtual reality and other wearable platforms because we can connect physical health with mental health using our test.
INN: Why should investors look at Cognetivity Neurosciences as a potential investment?
SH: Because there is a revolution coming in health care. To give you an idea of how big this industry is, twenty percent of the US economy is health care. We need to have substantial changes in how we approach health and how we provide health [care] in order to be able to tackle the problems we have, such as dementia. We are on the forefront of this change. We will use latest technologies and cutting edge findings in neuroscience…and then we can do something for our patients.
INN: So your technology has the potential to save the government a lot of money?
SH: Governments. Not only saving money but also providing better health. At the end of the day taxpayers are the ones paying for health care. It’s going to help everyone.
INN: Aside from the DPUK partnership, which was really exciting news, what other developments is Cognetivity Neurosciences looking forward to this year?
SH: Towards the end of last year, we signed a commercial agreement with a Swiss company. They … want to use our technology as a mental health monitor as an application, they can use it on daily basis. It’s not a medical product. This is not the core of what we’ve been doing on the clinical side. This is more of a health application that people can test themselves on daily basis and find ways that they can improve their mental health. We expect to have some breakthroughs on that front as well in the coming year. By the end of the year, we hope to complete the clinical trial and be ready to a have a commercial launch for our medical product.
Don’t forget to follow us @INN_Technology for real-time news updates!
Securities Disclosure: I, Bala Yogesh, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in contributed article. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.